Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Thursday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.03 on Thursday. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49. The stock has a market cap of $1.22 million, a PE ratio of 0.00 and a beta of 1.63. The company has a 50-day moving average of $0.03 and a two-hundred day moving average of $0.04.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.